The pharmacokinetics of megazol (CAS 19622-55-0) was investigated after intraperitoneal and oral administration of the drug (80 mg/kg) to mice. The plasma levels were significantly higher after oral administration of drug than after intraperitoneal route (33.8 mu g/ml compared with 19.0 mu g/ml for C-max, 158714 mu g.h/l compared with 96057 mu g.h/l for AUC). When suramin (CAS 145-63-1) was administered 24 h before oral administration of megazol, megazol absorption was accelerated (2 h compared with 4 h for T-max) but the amount absorbed was lower (19.9 mu g/ml compared with 33.8 mu g/ml for C-max and 95547 mu g.h/l vs 158714 mu g.h/l for AUG). In the infected mice previously treated with suramin, all estimated pharmacokinetic parameters of plasma megazol were significantly modified, in particularly an increase in the apparent volume of distribution (5.6 l/kg compared with 0.9 l/kg) with a prolongation of the elimination half-life (3 h compared with 0.7 h) of megazol. Excretion of the total radioactivity of megazol was also evaluated after oral administration of H-3-megazol to rats. Total radioactivity was eliminated predominantly via the urinary route (80 %) vs. 10.5 % in the faeces, 9.5 % remaining in the body 8 days after dosing. When unlabelled megazol was orally administered to rats with absence or presence of suramin, megazol recovered in urine and faeces 72 h dosing was: 55.7 % / 2 % vs 20.6 % / 1.6 %, respectively. In the urine, unchanged megazol was present as characterized by LC-MS/MS as well as 4 unknown metabolites. This study indicates that suramin significantly affects the pharmacokinetics of megazol and its elimination.